AstraZeneca, Oxford University resume clinical trials of COVID-19 vaccine

He said they "will be ready" in case of good indicators from the vaccine study, FDA and advisory committee and have already "started manufacturing and have already manufactured hundreds of thousands of doses" in preparation, Fox Business reported.

US-based pharmaceutical major Pfizer and German biotech firm BioNTech have announced to expand the enrollment of their Phase 3 Covid-19 vaccine trial to up to approximately 44,000 participants, up from an initial recruitment goal of 30,000 individuals.

Enrollment in the company's global trials of the vaccine, which it is developing with researchers at Oxford University, was put on pause on September 6.

"We go to younger people. Now we will go to 16 years old", he said.

The stock was the biggest boost to London's bluechip, FTSE 100 .FTSE index in early trading, but quickly pared gains as U.S. President Donald Trump's order to lower prices nationally hurt pharmaceutical stocks across the board.

Google is announcing the Pixel 5 on September 30
According to the invite, we'll be seeing a brand new Chromecast, an updated smart speaker, and the aforementioned phones. Livestream details are yet to be announced but it will most likely happen through YouTube.

Pfizer-BioNTech's BNT162mRNA vaccine is an mRNA vaccine. They want reports. I didn't want to have any of that.

Bourla said he gave Pfizer's team an "open checkbook" so they only have to worry about "scientific challenges". Plus, he added, he wanted to keep Pfizer out of politics, a tall task for a pharma company on any day, but especially during this pandemic.

While Bourla stopped short of predicting when Americans may be able to receive a coronavirus vaccine, Dr. Scott Gottlieb, former commissioner of the Food and Drug Administration and a member of Pfizer's board of directors, has stressed he does not believe a vaccine will be widely available until 2021.

"I think we should strive to have as more a diverse population as possible, but right now we are not bad". The trials also assess effectiveness by tracking who gets sick and who doesn't between patients getting the vaccine and those receiving a dummy shot. A prolonged delay in the U.S. trial could slow access to the vaccine in the US.

It had already been disclosed in July that the British government had reserved 60 million doses of Valneva's inactivated SARS-CoV-2 vaccine under development. "But it's not going to be used to achieve broad-based immunity, at least in 2020, perhaps in 2021".

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.